Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort
- PMID: 33186534
- DOI: 10.1016/S0140-6736(20)32233-9
Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort
Abstract
Background: Findings of historical studies suggest that elevated LDL cholesterol is not associated with increased risk of myocardial infarction and atherosclerotic cardiovascular disease in patients older than 70 years. We aimed to test this hypothesis in a contemporary population of individuals aged 70-100 years.
Methods: We included in our analysis individuals (aged 20-100 years) from the Copenhagen General Population Study (CGPS) who did not have atherosclerotic cardiovascular disease or diabetes at baseline and who were not taking statins. Standard hospital assays were used to measure LDL cholesterol. We calculated hazard ratios (HRs) and absolute event rates for myocardial infarction and atherosclerotic cardiovascular disease, and we estimated the number needed to treat (NNT) in 5 years to prevent one event.
Findings: Between Nov 25, 2003, and Feb 17, 2015, 91 131 individuals were enrolled in CGPS. During mean 7·7 (SD 3·2) years of follow-up (to Dec 7, 2018), 1515 individuals had a first myocardial infarction and 3389 had atherosclerotic cardiovascular disease. Risk of myocardial infarction per 1·0 mmol/L increase in LDL cholesterol was augmented for the overall population (HR 1·34, 95% CI 1·27-1·41) and was amplified for all age groups, particularly those aged 70-100 years. Risk of atherosclerotic cardiovascular disease was also raised per 1·0 mmol/L increase in LDL cholesterol overall (HR 1·16, 95% CI 1·12-1·21) and in all age groups, particularly those aged 70-100 years. Risk of myocardial infarction was also increased with a 5·0 mmol/L or higher LDL cholesterol (ie, possible familial hypercholesterolaemia) versus less than 3·0 mmol/L in individuals aged 80-100 years (HR 2·99, 95% CI 1·71-5·23) and in those aged 70-79 years (1·82, 1·20-2·77). Myocardial infarction and atherosclerotic cardiovascular disease events per 1000 person-years for every 1·0 mmol/L increase in LDL cholesterol were highest in individuals aged 70-100 years, with number of events lower with younger age. The NNT in 5 years to prevent one myocardial infarction or atherosclerotic cardiovascular disease event if all people were given a moderate-intensity statin was lowest for individuals aged 70-100 years, with the NNT increasing with younger age.
Interpretation: In a contemporary primary prevention cohort, people aged 70-100 years with elevated LDL cholesterol had the highest absolute risk of myocardial infarction and atherosclerotic cardiovascular disease and the lowest estimated NNT in 5 years to prevent one event. Our data are important for preventive strategies aimed at reducing the burden of myocardial infarction and atherosclerotic cardiovascular disease in the growing population aged 70-100 years.
Funding: None.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Comment in
-
Never too old to benefit from lipid-lowering treatment.Lancet. 2020 Nov 21;396(10263):1608-1609. doi: 10.1016/S0140-6736(20)32333-3. Epub 2020 Nov 10. Lancet. 2020. PMID: 33186536 No abstract available.
Similar articles
-
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28. Lancet. 2009. PMID: 19329177 Clinical Trial.
-
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22. Circ Cardiovasc Qual Outcomes. 2009. PMID: 20031900 Clinical Trial.
-
A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention.JAMA Cardiol. 2018 Nov 1;3(11):1090-1095. doi: 10.1001/jamacardio.2018.3476. JAMA Cardiol. 2018. PMID: 30422172 Free PMC article.
-
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.JAMA. 2016 Sep 27;316(12):1289-97. doi: 10.1001/jama.2016.13985. JAMA. 2016. PMID: 27673306 Review.
-
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.Atherosclerosis. 2018 Nov;278:135-142. doi: 10.1016/j.atherosclerosis.2018.08.040. Epub 2018 Aug 30. Atherosclerosis. 2018. PMID: 30273874 Review.
Cited by
-
The effects of aerobic exercise on cardiometabolic health in postmenopausal females: A systematic review and meta-analysis of randomized controlled trials.Womens Health (Lond). 2024 Jan-Dec;20:17455057241290889. doi: 10.1177/17455057241290889. Womens Health (Lond). 2024. PMID: 39431435 Free PMC article.
-
Reduced circulating CD63+ extracellular vesicle levels associate with atherosclerosis in hypercholesterolaemic mice and humans.Cardiovasc Diabetol. 2024 Oct 17;23(1):368. doi: 10.1186/s12933-024-02459-w. Cardiovasc Diabetol. 2024. PMID: 39420340 Free PMC article.
-
Genetic support of causal association between lipid and glucose metabolism and stress urinary incontinence in women: a bidirectional Mendelian randomization and multivariable-adjusted study.Front Endocrinol (Lausanne). 2024 Sep 16;15:1394252. doi: 10.3389/fendo.2024.1394252. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39351534 Free PMC article.
-
Role of Gut Microbial Metabolites in Cardiovascular Diseases-Current Insights and the Road Ahead.Int J Mol Sci. 2024 Sep 23;25(18):10208. doi: 10.3390/ijms251810208. Int J Mol Sci. 2024. PMID: 39337693 Free PMC article. Review.
-
Investigating Genetic Overlap between Alzheimer's Disease, Lipids, and Coronary Artery Disease: A Large-Scale Genome-Wide Cross Trait Analysis.Int J Mol Sci. 2024 Aug 13;25(16):8814. doi: 10.3390/ijms25168814. Int J Mol Sci. 2024. PMID: 39201500 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
